Abstract
Monoclonal antibodies (mAbs) based-therapies are currently one of the most successful strategies to treat immune disorders, cancer and infectious diseases. Vectors derived from adenoassociated virus (AAV) are very attractive to deliver the genes coding the mAbs because they allow long-term expression thus, reducing the number of administrations. They can also penetrate biological barriers such as the blood-brain-barrier to transduce cells localized in immunoprivileged organs. Recent animal studies with AAV have demonstrated the capacity of AAV to deliver sufficient quantity of antibodies to confer an efficient immunoprotection against chronic and infectious diseases for several months to years. The treatment was successfully applied either for prophylaxis or therapeutic use, depending on the disease and its progression. In this review, we discuss the advantages and the limitations of AAV for mAb and immunoadhesin delivery. Recent advances in vector design and antibody engineering are also presented. Optimization of the vector design can improve the kinetic and the level of mAbs expression whereas protein engineering can enhance transgene product properties. Furthermore, an exhaustive review of pre-clinical studies for chronic diseases including Alzheimer disease, amyotrophic lateral sclerosis and cancer is presented as well as for infectious diseases.
Keywords: Monoclonal antibodies, Recombinant adeno-associated virus, Antibody delivery, Chronic and infectious diseases, Vector design.
Current Gene Therapy
Title:Antibody Delivery Mediated by Recombinant Adeno-associated Virus for the Treatment of Various Chronic and Infectious Diseases
Volume: 16 Issue: 6
Author(s): Marc-André Robert, Rénald Gilbert and Bruno Gaillet*
Affiliation:
- Université Laval, Département de génie chimique, Université Laval, Room #3570, 1065 avenue de la Médecine, Pavillon Adrien-Pouliot, Québec G1V 0A6, QC, Canada,Canada
Keywords: Monoclonal antibodies, Recombinant adeno-associated virus, Antibody delivery, Chronic and infectious diseases, Vector design.
Abstract: Monoclonal antibodies (mAbs) based-therapies are currently one of the most successful strategies to treat immune disorders, cancer and infectious diseases. Vectors derived from adenoassociated virus (AAV) are very attractive to deliver the genes coding the mAbs because they allow long-term expression thus, reducing the number of administrations. They can also penetrate biological barriers such as the blood-brain-barrier to transduce cells localized in immunoprivileged organs. Recent animal studies with AAV have demonstrated the capacity of AAV to deliver sufficient quantity of antibodies to confer an efficient immunoprotection against chronic and infectious diseases for several months to years. The treatment was successfully applied either for prophylaxis or therapeutic use, depending on the disease and its progression. In this review, we discuss the advantages and the limitations of AAV for mAb and immunoadhesin delivery. Recent advances in vector design and antibody engineering are also presented. Optimization of the vector design can improve the kinetic and the level of mAbs expression whereas protein engineering can enhance transgene product properties. Furthermore, an exhaustive review of pre-clinical studies for chronic diseases including Alzheimer disease, amyotrophic lateral sclerosis and cancer is presented as well as for infectious diseases.
Export Options
About this article
Cite this article as:
Robert Marc-André, Gilbert Rénald and Gaillet Bruno*, Antibody Delivery Mediated by Recombinant Adeno-associated Virus for the Treatment of Various Chronic and Infectious Diseases, Current Gene Therapy 2016; 16 (6) . https://dx.doi.org/10.2174/1566523217666170102111251
DOI https://dx.doi.org/10.2174/1566523217666170102111251 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dementia and the Default Mode
Current Alzheimer Research Imaging of Sigma1 Receptors in the Human Brain Using PET and [11C]SA4503
Central Nervous System Agents in Medicinal Chemistry Histopathology Image Analysis and Classification Using ARMA Models: Application to Brain Cancer Detection
Current Medical Imaging A New Frontier in the Treatment of Cancer: NK-1 Receptor Antagonists
Current Medicinal Chemistry MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry Recent Advances in Structure and Function Studies on Human Bitter Taste Receptors
Current Protein & Peptide Science Chemistry and Pharmacological Properties of Some Natural and Synthetic Antioxidants for Heavy Metal Toxicity
Current Medicinal Chemistry Physiological Changes in the Critically Ill Patient with Sepsis
Current Pharmaceutical Biotechnology 5-Sulfonamide Benzimidazoles: A Class of Cannabinoid Receptors Agonists with Potent In Vivo Antinociception Activity
Letters in Drug Design & Discovery Minocycline and Doxycycline: More Than Antibiotics
Current Molecular Pharmacology Calpain as a Potential Therapeutic Target in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Control and Role of Plateau Potential Properties in the Spinal Cord
Current Pharmaceutical Design Molecular Recognition of Tachykinin Receptor Selective Agonists: Insights from Structural Studies
Mini-Reviews in Medicinal Chemistry Study on the Development of a Cyclohexane Based Tripodal Molecular Device as "OFF-ON-OFF" pH Sensor and Fluorescent Iron Sensor
Current Analytical Chemistry Therapeutic Potential of the Modulation of Sphingosine-1-Phosphate Receptors
Current Medicinal Chemistry Quality, not Quantity: The Role of Natural Products and Chemical Proteomics in Modern Drug Discovery
Combinatorial Chemistry & High Throughput Screening Summary of Information on the Effects of Ionizing and Non-ionizing Radiation on Cytochrome P450 and Other Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism Enkephalinase Inhibitors: Potential Agents for the Management of Pain
Current Drug Targets Modelling the Neurovascular Unit and the Blood-Brain Barrier with the Unique Function of Pericytes
Current Neurovascular Research Medicinal Chemistry of Antimigraine Drugs
Current Medicinal Chemistry